Sarepta Therapeutics, Inc. (SRPT) Financial Statements
Sarepta Therapeutics, Inc. (SRPT) reported trailing twelve-month revenue of $2.0B (down 20.4% year on year) and net income of -$136.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $81.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SRPTSarepta Therapeutics, Inc.Follow SRPT — free
—
Price chart with a free account
- Market cap
- 1.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.01 | 0.15 | 0.30 | 0.38 | 0.54 | 0.70 | 0.93 | 1.24 | 1.90 | 2.20 | 1.97 | |
| Gross profit | 0.01 | — | — | — | — | — | — | — | — | 2.17 | — | |
| Research & development | 0.19 | 0.17 | 0.40 | 0.56 | 0.72 | 0.77 | 0.88 | 0.88 | 0.80 | 1.52 | 0.79 | |
| Operating income | -0.27 | -0.17 | -0.34 | -0.71 | -0.56 | -0.46 | -0.54 | -0.27 | 0.22 | -0.70 | -0.14 | |
| Pre-tax income | — | -0.05 | -0.36 | -0.71 | -0.55 | -0.42 | -0.69 | -0.52 | 0.26 | -0.70 | -0.13 | |
| Income tax | — | 0.00 | -0.00 | 0.00 | 0.00 | -0.00 | 0.01 | 0.02 | 0.03 | 0.01 | 0.01 | |
| Net income | -0.27 | -0.05 | -0.36 | -0.72 | -0.55 | -0.42 | -0.70 | -0.54 | 0.24 | -0.71 | -0.14 | |
| Diluted EPS ($) | -5.49 | -0.86 | -5.46 | -9.71 | -7.11 | -5.15 | -8.03 | -5.80 | 2.34 | -7.13 | -1.10 | |
| Diluted shares (bn) | — | 0.059 | 0.066 | 0.074 | 0.078 | 0.081 | 0.088 | 0.092 | 0.108 | 0.100 | — |
USD billions · SEC XBRL
Sarepta Therapeutics, Inc. — questions
- What is Sarepta Therapeutics, Inc.'s revenue?
- $2.0B over the twelve months to 2026-06-30, down 20.4% year on year, from its 10-Q and 10-K filings.
- What is Sarepta Therapeutics, Inc.'s net income?
- -$136.7M over the twelve months to 2026-06-30.
- What is Sarepta Therapeutics, Inc.'s free cash flow?
- $81.8M over the twelve months to 2026-06-30.
- What are Sarepta Therapeutics, Inc.'s diluted earnings per share?
- $-1.10 over the twelve months to 2026-06-30.
Every figure on this page comes from Sarepta Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.